Biotech adopts multi-dimensional business model
Bharat Biotech has made
significant strides in manufacturing and commercializing vaccines for
immunization programs worldwide.
Bharat Biotech International Ltd (BBIL) has achieved an annual turnover
of Rs 234.13 crore in 2008-09 as against Rs 126 crore in 2007-08 and
the company is expecting to touch Rs 300 crore in the year ahead.
Bharat Biotech has evolved as a multi-dimensional biotechnology company
specializing in product-oriented research, development and
manufacturing of vaccines and biotherapeutics. Hyderabad-based Bharat
Biotech is one of the largest manufacturers of INDIRAB (anti-rabies
vaccine) in India. Bharat Biotech is a WHO prequalified manufacturer of
REVAC-B (hepatitis-B vaccine) for supply to UNICEF and the only vaccine
company in India to manufacture and supply a preservative (thiomersol)
free vaccine, REVAC-Bmcf.
Bharat Biotech has developed a 3-dimensional business model with
emphasis on biogenerics, contract manufacturing and research for
developing novel products. This strategy has given Bharat Biotech the
ability to earn revenues in the short and medium term while focusing on
novel patent protected products that are much needed by the
Bharat Biotech has shown significant progress in new product
development and has partnered with companies from the US and Europe to
co-develop, manufacture and market the products. Bharat Biotech has
built productive partnerships with companies, such as Wyeth and
Agennix. Bharat Biotech is one of the first companies in India to
perform contract manufacturing of vaccines for global major like Wyeth,
due to the IPR associated with its Hib vaccine.
Other major partnerships of Bharat Biotech are with the Department of
Biotechnology, Government of India; PATH; US Centers for Disease
Control and Prevention (CDC); Stanford University; US National
Institutes of Health, National Institute of Allergy and Infectious
Diseases (NIAID); Society for Applied Studies; National Institute of
Immunology; Indo-US Vaccine Action Program; International Center for
Genetic Engineering and Biotechnology (ICGEB), Thrombogenics and All
India Institute of Medical Sciences.
Bharat Biotech is also now focused on developing several technology
parks. According to Dr Krishna Ella, chairman and managing director of
Bharat Biotech, the company’s task is to development core
infrastructure and technology to enable establishment of new companies
whereby new local entrepreneurs in the biotechnology field will be